The new FDA labeling for ESA-implications for patients and providers

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 2, 2012, Pages 348-353

  Manns, Braden J ^a,b,c   Tonelli, Marcello ^c,d  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c Alberta Kidney Disease Network   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ALLOIMMUNIZATION; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG LABELING; FOOD AND DRUG ADMINISTRATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; MEDICAL DECISION MAKING; MEDICAL PRACTICE; META ANALYSIS (TOPIC); MORTALITY; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE; THROMBOSIS; TREATMENT INDICATION; VASCULAR ACCESS;

ANEMIA; BIOLOGICAL MARKERS; CHRONIC DISEASE; DRUG LABELING; EVIDENCE-BASED MEDICINE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84857153506     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.09960911     Document Type: Article

References (21)

1. FDA: FDA Drug Safety Communication: Modified Dosing Recommendations to Improve the Safe Use of Erythropoiesis-Stimulating Agents in Chronic Kidney Disease, 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm. Accessed November 15, 2011
2. Tonelli MKS, Wiebe N, Shrive F, Hemmelgarn B, Manns B: Erythropoiesis-Stimulating Agents for Anemia of Chronic Kidney Disease: Systematic Review and Economic Evaluation. Technology Report Number 106, Ottawa, Canada, Canadian Agency for Drugs and Technologies in Health, 2008
3. Bahlmann J, Schöter KH, Scigalla P, Gurland HJ, Hilfenhaus M, Koch KM, Muthny FA, Neumayer HH, Pommer W, Quelhorst E: Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: A controlled study. Contrib Nephrol 88: 90-106, 1991
4. Canadian Erythropoietin Study Group: Association between re-combinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 300: 573-578, 1990
5. Collins AJ, Ma JZ, Xia A, Ebben J: Trends in anemiatreatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 32 [Suppl 4]: S133-S141, 1998
6. Fleming TR, DeMets DL: Surrogate end points in clinical trials: Are we being misled? Ann Intern Med 125: 605-613, 1996
7. Manns B, Owen WF, Winkelmayer WC, Devereaux PJ, Tonelli M: Surrogate markers in clinical studies: Problems solved or created? Am J Kidney Dis 48: 159-166, 2006
8. National Kidney Foundation: KDOQI: Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47[Suppl 3]: S1-S146, 2006
9. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998
10. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032, 2009.
11. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006
12. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006
13. Phrommintikul A, Haas SJ, Elsik M, Krum H: Mortality and target hemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369: 381-388, 2007
14. Clement FM, Klarenbach S, Tonelli M, Johnson JA, Manns BJ: The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: A systematic review and meta-analysis. Arch Intern Med 169: 1104-1112, 2009
15. Wyrwich KW, Tierney WM, Babu AN, Kroenke K, Wolinsky FD: A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease. Health Serv Res 40: 577-591, 2005
16. Norman GR, Sloan JA, Wyrwich KW: Interpretation of changes in health-related qualityoflife: The remarkable universality ofhalf a standard deviation. Med Care 41: 582-592, 2003
17. Panichi V, Rosati A, Bigazzi R, Paoletti S, Mantuano E, Beati S, Marchetti V, Bernabini G, Grazi G, Rizza GM, Migliori M, Giusti R, Lippi A, Casani A, Barsotti G, Tetta C RISCAVID Study Group: Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: Results from the RISCAVID study. Nephrol Dial Transplant 26: 2641-2648, 2011
18. Klarenbach SW, Moist LM, Foley RN, Barrett BJ, Madore F, White CT, Culleton BF, Tonelli M, Manns BJ Canadian Society of Nephrology: Clinical practice guidelines for supplemental therapies and issues. Kidney Int Suppl 110: S19-S24, 2008
19. Collins AJ, Brenner RM, Ofman JJ, Chi EM, Stuccio-White N, Krishnan M, Solid C, Ofsthun NJ, Lazarus JM: Epoetin alfa use in patients with ESRD: An analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 46: 481-488, 2005
20. Moist LM, Foley RN, Barrett BJ, Madore F, White CT, Klarenbach SW, Culleton BF, Tonelli M, Manns BJ Canadian Society of Nephrology: Clinical practice guidelines for evidence-based use of erythropoietic-stimulating agents. Kidney Int Suppl 110: S12-S18, 2008
21. Brimble KS, Rabbat CG, McKenna P, Lambert K, Carlisle EJ: Protocolized anemia management with erythropoietin in he-modialysis patients: a randomized controlled trial. J Am Soc Nephrol 14: 2654-2661, 2003